Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43841   clinical trials with a EudraCT protocol, of which   7281   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-005491-41
    Sponsor's Protocol Code Number:B1931022
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-05-10
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2011-005491-41
    A.3Full title of the trial
    An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator?s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
    Estudio en Fase 3, abierto y aleatorizado de ozogamicina de inotuzumab comparado con un fármaco definido elegido por el investigador en pacientes adultos con leucemia linfoblástica aguda (LLA) positiva al CD22, recidivante o refractaria
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase 3 Study of Inotuzumab Ozogamicin versus Investigator's Choice of Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
    Estudio en Fase 3 de ozogamicina de inotuzumab versus quimioterapia elegida por el investigador en pacientes con leucemia linfoblástica aguda recidivante o refractaria.
    A.4.1Sponsor's protocol code numberB1931022
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPfizer S.L.U.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPfizer Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPfizer Inc
    B.5.2Functional name of contact pointClinical Trials.gov Call Center
    B.5.3 Address:
    B.5.3.1Street Address235 E 42nd Street
    B.5.3.2Town/ cityNew York
    B.5.3.3Post codeNY 10017
    B.5.3.4CountryUnited States
    B.5.4Telephone number+0018007181021
    B.5.5Fax number+0013037391119
    B.5.6E-mailClinicalTrials.govCallCenter@pfizer.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameInotuzumab Ozogamicin
    D.3.2Product code PF-05208773
    D.3.4Pharmaceutical form Lyophilisate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number N/A
    D.3.9.2Current sponsor codeCMC-544
    D.3.9.3Other descriptive nameinotuzumab ozogamicin
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeanticuerpo monoclonal IgG4 humanizado anti-CD22 y conjugado con caliqueamicina
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name CYTOSAR, 500mg, powder and solvent for solution for injection
    D.2.1.1.2Name of the Marketing Authorisation holderPfizer
    D.2.1.2Country which granted the Marketing AuthorisationPoland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCytarabine 500 mg
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCYTARABINE
    D.3.9.1CAS number 147-94-4
    D.3.9.3Other descriptive namecytarabine 500mg powder for solution for infusion
    D.3.9.4EV Substance CodeSUB06880MIG
    D.3.10 Strength
    D.3.10.1Concentration unit g gram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name CYTOSAR 1 g
    D.2.1.1.2Name of the Marketing Authorisation holderPfizer
    D.2.1.2Country which granted the Marketing AuthorisationCzech Republic
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCytarabine 1 g
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCYTARABINE
    D.3.9.1CAS number 147-94-4
    D.3.9.3Other descriptive namecytarabine 1 gram powder for solution for infusion
    D.3.9.4EV Substance CodeSUB06880MIG
    D.3.10 Strength
    D.3.10.1Concentration unit g gram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Neupogen 600 µg/ml
    D.2.1.1.2Name of the Marketing Authorisation holderAmgen Europe BV
    D.2.1.2Country which granted the Marketing AuthorisationPoland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFilgrastim
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFILGRASTIM
    D.3.9.1CAS number 121181-53-1
    D.3.9.3Other descriptive namefilgrastim 300 µg (600 µg/ml) solution for injection in a prefilled syringe
    D.3.9.4EV Substance CodeSUB07627MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number600
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Neupogen 960 µg/ml
    D.2.1.1.2Name of the Marketing Authorisation holderAmgen Europe BV
    D.2.1.2Country which granted the Marketing AuthorisationPoland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFilgrastim
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFILGRASTIM
    D.3.9.1CAS number 121181-53-1
    D.3.9.3Other descriptive namefilgrastim 480 µg (960 µg /ml) solution for injection in a prefilled syringe
    D.3.9.4EV Substance CodeSUB07627MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number960
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Fludarabine Actavis 50 mg
    D.2.1.1.2Name of the Marketing Authorisation holderActavis UK Ltd
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFludarabine 50 mg
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFLUDARABINE
    D.3.9.1CAS number 21679-14-1
    D.3.9.3Other descriptive namefludarabine 50mg Lyophilisate for Solution for Infusion
    D.3.9.4EV Substance CodeSUB07678MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Mitoxantrone (Mitozantrone) 2 mg/ml
    D.2.1.1.2Name of the Marketing Authorisation holderHospira UK Ltd
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMitoxantrone 2 mg/ml
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 65271-80-9
    D.3.9.3Other descriptive namemitoxantrone 2 mg/ml concentrate for solution for infusion
    D.3.9.4EV Substance CodeSUB09012MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
    Leucemia linfoblástica aguda de células B recidivante o refractaria
    E.1.1.1Medical condition in easily understood language
    Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
    Leucemia linfoblástica aguda (LLA) recidivante o refractaria
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the hematological remission, defined as CR (both CR and CRi), as reported by the external independent endpoint adjudication committee, in patients with relapsed/refractory ALL randomized to receive inotuzumab ozogamicin (Arm A) versus patients randomized to receive active comparator (Arm B).
    Comparar la remisión hematológica, definida como RC (RC y RCi), notificada por un Comité independiente de adjudicación externo, en pacientes con LLA recidivante/refractaria aleatorizados para recibir ozogamicina de inotuzumab (Grupo A) frente a pacientes aleatorizados para recibir un comparador activo (Grupo B).
    E.2.2Secondary objectives of the trial
    Safety and efficacy endpoints will be compared between the inotuzumab ozogamicin arm and the active comparator arm and will include:
    Key Secondary Objective: •To compare the overall survival (OS) of patients with relapsed/refractory ALL.
    Other Secondary Objectives:
    •To compare the duration of response (DoR)
    •To compare the progression-free survival (PFS)
    •To compare the time to progression (TTP)
    •To compare the rate of stem-cell transplantation in patients
    •To characterize the safety and tolerability including the rate of VOD (veno-occlusive disease)/SOS (sinusoidal obstruction syndrome) following allogeneic stem cell transplant
    •To assess minimal residual disease (MRD) levels and cytogenetics in patients achieving a CR/CRi
    •To determine the population pharmacokinetic parameters of inotuzumab ozogamicin and confirm sources of exposure variability
    •To compare patient-reported health-related quality of life (HRQOL) and patient-reported health status between treatment arms
    Los criterios de valoración de seguridad y eficacia se compararán entre grupo de ozogamicina de inotuzumab y del comparador activo. Incluirán:
    Objetivo secund. princip.: Supervivencia global-SG de los pac. con LLA recidivante o refractaria
    Otros objet. secund.:
    •Comparar duración la respuesta-DdR
    •Comparar supervivencia sin progresión-SSP
    •Comparar tiempo hasta progresión-THP
    •Comparar tasa de transplantes de células germinales de los pac.
    •Describir seguridad y tolerabilidad, incluida tasa de enfermedad venooclusiva-EVO y síndrome de obstrucción sinusoidal-SOS después de transplante de células germinales alogénico
    •Evaluar niveles de enfermedad residual mínima-ERM y citogenética en los pac. que alcancen RC/RCi
    •Determinar los parámetros de farmacocinética poblacional de ozogamicina de inotuzumab y confirmar los orígenes de la variabilidad de exposición
    •Comparar calidad de vida relacionada con salud-CdVRS y estado de salud notificados por los pac. entre grupos de tratam
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Patient eligibility should be reviewed and documented by an appropriately qualified member of the investigator’s study team before patients are included in the study. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:
    1. Relapsed or refractory CD22-positive ALL (ie, ≥ 20% blasts CD22-positive) due to receive either salvage 1 or salvage 2 therapy and for which either arm of randomized study therapy offers a reasonable treatment option. Ph+ ALL patients must have failed treatment with at least 1 second generation tyrosine kinase inhibitor;
    2. Patients in Salvage 1 with late relapse should be deemed poor candidates for reinduction with initial therapy;
    3. Bone marrow involvement with ≥ 5% lymphoblasts;
    4. Age 18 years or older;
    5. ECOG performance status 0 – 2;
    6. Adequate liver function, including total serum bilirubin ≤1.5 x ULN unless the patient has documented Gilbert syndrome, and aspartate and alanine aminotransferase (AST and ALT) ≤2.5 x ULN. If organ function abnormalities are considered due to tumor, total serum bilirubin must be ≤2 x ULN;
    7. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or any serum creatinine level associated with a measured or calculated creatinine clearance of ≥40 mL/min;
    8. Male and female patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for a minimum of 90 days after the last dose of assigned treatment. A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active. Female patients who are not of childbearing potential (ie, meet at least one of the following criteria):
    • Have undergone hysterectomy or bilateral oophorectomy; or
    • Have medically confirmed ovarian failure; or
    • Are medically confirmed to be post-menopausal (cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause.
    9. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legal representative) has been informed of all pertinent aspects of the study;
    10. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
    Un miembro cualificado del equipo de estudio del investigador revisará y documentará la elegibilidad del paciente antes de la inclusión del paciente en el estudio. Para poder ser incluidos en el estudio, los pacientes deberán cumplir todos los criterios de inclusión siguientes:
    1. LLA CD22-positiva recidivante o refractaria (es decir, ≥20% blastos CD22-positivos) para recibir terapia de rescate 1 o rescate 2 y para quienes cualquiera de los grupos de tratamiento de estudio aleatorizado ofrezca una opción de tratamiento razonable. En los pacientes con LLA Ph+ debe haber fracasado el tratamiento con al menos 1 inhibidor tirosincinasa de segunda generación;
    2. Los pacientes en 1º rescate con recidiva tardía deberán ser considerados poco candidatos para la einducción con la erapia inicial;
    3. Afectación de la médula ósea con ≥ 5% de linfoblastos;
    4. Edad 18 años o mayor;
    5. Estado funcional ECOG 0 – 2;
    6. Función hepática adecuada, con bilirrubina total sérica ≤1,5 x LSN a menos que el paciente presente un síndrome de Gilbert documentado, y aspartato y alanina aminotransferasas (AST y ALT) ≤2,5 x LSN. Se considera que las alteraciones de la función orgánica se debe al tumor, la bilirrubina total sérica debe ser ≤2 x LSN;
    7. Creatinina sérica 1,5 x límite superior de la normalidad (LSN) o cualquier nivel de creatinina sérica asociado a una determinación o cálculo del aclaramiento de creatinina ≥40 ml/min.;
    8. Las mujeres y hombres potencialmente fértiles deberán acordar y comprometerse a usar un método anticonceptivo fiable durante todo el estudio y como mínimo hasta 90 días después de la última dosis del tratamiento asignado. Un paciente es potencialmente fértil si, en opinión del investigador, es biológicamente capaz de engendrar un hijo y es sexualmente activo. Las pacientes mujeres no se consideran potencialmente fértiles si cumplen alguno de los criterios siguientes):
    • Han sido sometidas a histerectomía u ooforectomía bilateral; o
    • Presentan un fracaso ovárico confirmado médicamente; o
    • Son posmenopáusicas confirmadas médicamente (cese de las menstruaciones regulares durante al menos 12 meses consecutivos sin una causa patológica o fisiológica alternativa.
    9. Constancia de consentimiento informado firmado personalmente que indique que el paciente (o su representante legal) ha sido informado de todos los aspectos pertinentes del estudio;
    10. Disposición y capacidad de cumplir las visitas programadas, los planes de tratamiento, las pruebas analíticas y otros procedimientos del estudio.
    E.4Principal exclusion criteria
    Patients presenting with any of the following will not be included in the study:
    1. Isolated extramedullary relapse (i.e. testicular or CNS);
    2. Burkitt’s or mixed lineage leukemia;
    3. Active central nervous system (CNS) leukemia, as defined by unequivocal morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF), use of CNS-directed local treatment for active disease within the prior 28 days, symptomatic CNS leukemia (i.e. cranial nerve palsies or other significant neurologic dysfunction) within 28 days. Prophylactic intrathecal medication is not a reason for exclusion;
    4. Prior chemotherapy within ≤ 2 weeks before randomization with the following exceptions: steroids, hydroxyurea, oral mercaptopurine, methotrexate, vincristine, thioguanine, and tyrosine kinase inhibitors are permitted within 2 weeks of randomization as maintenance or to reduce the peripheral blood blast count.

    Patients must have recovered from acute non hematologic toxicity (to ≤ Grade 1) of all previous therapy prior to enrollment.

    5. Prior monoclonal antibodies within 6 weeks of randomization;
    6. Prior allogeneic hematopoietic stem cell transplant (HSCT) or other anti-CD22 immunotherapy ≤ 4 months before randomization. Patients must have completed immunosuppression therapy for treatment of GvHD prior to enrollment. At randomization, patients must not have > grade 2 acute GvHD, or extensive chronic GvHD;
    7. Peripheral absolute lymphoblast count > 10,000 /µL (treatment with hydroxyurea and/or steroids is permitted within 2 weeks of randomization to reduce the WBC count);
    8. Known systemic vasculitides (eg, Wegener’s granulomatosis, polyarteritis nodosa, systemic lupus erythematosus), primary or secondary immunodeficiency (such as HIV infection or severe inflammatory disease);
    9. Current or chronic hepatitis B or C infection as evidenced by hepatitis B surface antigen and anti-hepatitis C antibody positivity, respectively, or known seropositivity for human immunodeficiency virus (HIV). HIV testing may need to be performed in accordance with local regulations or local practice;
    10. Major surgery within ≤4 weeks before randomization;
    11. Unstable or severe uncontrolled medical condition (eg, unstable cardiac function or unstable pulmonary condition);
    12. Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of the cervix, or localized prostate cancer that has been definitely treated with radiation or surgery. Patients with previous malignancies are eligible provided that they have been disease free for ≥2 years;
    13. Cardiac function, as measured by left ventricular ejection fraction (LVEF) that is less than 45%, or the presence of New York Heart Association (NYHA) stage III or IV congestive heart failure;
    14. Patients with active heart disease (NYHA class ≥ 3 as assessed by history and physical examination);
    15. QTcF > 470 msec (based on the average of 3 consecutive ECGs);
    16. Myocardial infarction ≤6 months before randomization;
    17. History of clinically significant ventricular arrhythmia, or unexplained syncope not believed to be vasovagal in nature, or chronic bradycardic states such as sinoatrial block or higher degrees of AV block unless a permanent pacemaker has been implanted;
    18. Uncontrolled electrolyte disorders that can compound the effects of a QTc prolonging drug (eg. hypokalemia, hypocalcemia, hypomagnesemia);
    19. History of chronic liver disease (eg, cirrhosis) or suspected alcohol abuse;
    20. History of hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS);
    21. Administration of live vaccine ≤6 weeks before randomization;
    22. Evidence of uncontrolled current serious active infection (including sepsis, bacteremia, fungemia) or patients with a recent history (within 4 months) of deep tissue infections such as fascitis or osteomyelitis;
    23. Patients who have had a severe allergic reaction or anaphylactic reaction to any humanized monoclonal antibodies;
    24. Pregnant females; breastfeeding females; males and females of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for a minimum of 90 days after the last dose of investigational product;
    25. Patients who are investigational site staff members or relatives of those site staff members or patients who are Pfizer employees directly involved in the conduct of the trial;
    26. Participation in other investigational studies during active treatment phase;
    27. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
    No se incluirá en el ensayo pac. que presenten alguno de los criterios siguientes:
    1-Recidiva extramedular aislada
    2-Leucemia deBurkitt o leucemia de linaje mixto(es decir testicular o del SNC)
    3-Leucemia del SNC activa definida por la prueba morfológica inequívoca de linfoblastos en el LCR, uso de tratamiento local dirigido al SNC en los 28 días anteriores, leucemia del SNC sintomática(es decir parálisis de los nervios craneales u otras disfunciones neurológicas significativas)en los 28días anteriores. La medicación intratecal profiláctica no es una razón para la exclusión
    4-Quimioterapia previa en las≤2semanas antes de la aleatorización, excepciones: esteroides, hidroxiurea, mercaptopurina oral, metotrexato, vincristina, tioguanina, e inhibidores de la tirosincinasa en las 2 semanas previas a la aleatorización como mantenimiento o para reducir el recuento de blastos en sangre periférica
    Los pac.se deben haber recuperado de las toxicidades agudas no hematológicas(hasta ≤Grado1) de todos los tratamientos previos antes de la inclusión
    5-Anticuerpos monoclonales en las 6 semanas previas a la aleatorizac.
    6-Transp. alogénico de células germinales hematopoyéticas(TCGH) previo u otros tipos de inmunoterapia anti-CD22 ≤4 meses antes de la aleatorizac. Los pac. deben haber finalizado la terapia inmunosupresora para el tto. de la EIcH antes de la inclusión. Durante la aleatoriz., los pac. no deben presentar enfermedad del injerto contra el huésped(EIcH)>grado2 o EIcH extensa crónica
    7-Recuento de linfoblastos periféricos absolutos>10.000/µL(se permite el tto. con hidroxiurea y/o esteroides en las 2semanas previas a la aleatorización para reducir el recuento leucocitario)
    8-Vasculitis sistémica conocida(ej.granulomatosis de Wegener, poliarteritis nodosa, lupus eritematoso sistémico), inmunodeficiencia primaria o secundaria (como infección porVIH o enferm. inflamatoria grave)
    9-Infección por hepatitis B o C actual o crónica probada por la positividad del antígeno de superficie de la hepatitis B o de los anticuerpos antihepatitis C, respectivamente, o seropositividad conocida al VIH. La pruebas delVIH se podrán realizar según las normativas o la práctica local
    10-Cirugía mayor en las≤4semanas anteriores a la aleatoriz.
    11-Patología médica inestable o grave no controlada(ej.función cardiaca inestable o patología pulmonar inestable
    12-Neoplasia maligna activa concurrente u otros cánceres cutáneos no melanomatosos, carcin. cervical in situ o cáncer de próstata localizado tratados definitivamente con radiación o cirugía. Los pac. con neoplasias malignas previas son elegibles siempre y cuando hayan estado libres de enfermedad durante≥2 años
    13-Func. cardiaca, determinada por la fracción de eyecciónventricular izquierda (FEVI) inferior al45%, o presencia de insuficiencia cardiaca congestiva en estadío III oIV de la NewYorkHeart Association (NYHA)
    14-Pac. con enfer. cardiaca activa(clase NYHA≥3 evaluada mediante la historia y la exploración física)
    15-QTcF>470 mseg.(en base al promedio de 3ECG consecutivos)
    16-Infarto de miocardio≤6 meses antes de la aleatoriz.
    17-Antec.de arritmia ventricular clínicamente significativa o síncopa inexplicada no considerada de naturaleza vasovagal, o estados bradicárdicos crónicos como bloqueo sinoauricular o bloqueo AV de grado más elevado, a menos que se haya implantado un marcapasos permanente
    18-Trastornos electrolíticos no controlados que puedan agravar los efectos de un fármaco que prolongue el QTc (p.ej., hipokaliemia, hipocalcemia, hipomagnesemia)
    19-Antec.de enfer.hepática crónica(p.ej., cirrosis) o sospecha de abuso del alcohol
    20-Antec.de enfer. venooclusiva(EVO) o síndrome de obstrucción sinusoidal(SOS)
    21-Administración de vacuna de virus vivos ≤6 semanas antes de la aleatoriz.
    22-Prueba de infección grave activa en curso(incluida la sepsis, bacteriemia, fungemia, o pacientes con antecedentes recientes(en los 4 meses anteriores) de infecciones de tejidos profundos como fasc itis o osteomielitis
    23-Pac. que hayan presentado una reacción alérgica intensa o una reacción anafiláctica a algún anticuerpo monoclonal humanizado
    24-Mujeres embarazadas; muj. en periodo de lactancia; hombres y mujeres potencialmente fértiles que no utilicen un método de contracepción efectivo o no estén de acuerdo en continuarlo durante un mínimo de 90días después de la última dosis del producto en investigación
    25-Pac. miembros del personal del centro de investigación o familiares de estos miembros del personal del centro o pac. que sean empleados de Pfizer directamente involucrados en la realización del ensayo
    26-Participación en otros estudios de investigación durante la fase de tto. activo
    27-Cualquier otra patología médica o psiquiátrica grave, aguda o crónica o anomalía analítica que, en opinión del investigador, pueda incrementar el riesgo asociado a la particip. del pac. en el estudio o la administración del producto en investig., o pueda interferir la interpretación...
    E.5 End points
    E.5.1Primary end point(s)
    - CR and CRi.
    - RC y RCi.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Dependent on individual patient response
    Depende de la respuesta individual del paciente
    E.5.2Secondary end point(s)
    ? OS (Key secondary endpoint);
    ? DoR;
    ? PFS;
    - Number of Transplants;
    - Adverse events and laboratory abnormalities (CTCAE v3.0 grade, timing, seriousness and relatedness);
    - MRD and cytogenetics in responding patients;
    - PK;
    - EORTC QLQ-C30 and EQ-5D.
    - SG (principal criterio de valoración secundario);
    - DdR;
    - SSP;
    - Número de transplantes;
    - Acontecimientos adversos y alteraciones analíticas (grado CTCAE v3.0, tiempo, gravedad y relación);
    - DMR y citogenética en pacientes que responden;
    - FC;
    - EORTC QLQ-C30 y EQ-5D
    E.5.2.1Timepoint(s) of evaluation of this end point
    Dependent on individual patient response
    Dependen de la respuesta individual del paciente
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA40
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Brazil
    Canada
    China
    Croatia
    Czech Republic
    Finland
    France
    Germany
    Hungary
    Italy
    Japan
    Korea, Republic of
    Poland
    Serbia
    Singapore
    Slovakia
    Spain
    Sweden
    Taiwan
    Thailand
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of Trial in all participating countries is defined as the Last Patient Last Visit (inclusive of long term follow-up visits, see section 6.4 of the protocol), unless stopped earlier by the external data monitory committee (E-DMC).
    El final del ensayo en todos los países participantes se define como la última visita del último paciente (incluidas las visitas de seguimiento a largo plazo, ver apartado 6.4), a menos que sea cancelado tempranamente por el comité de supervisión de datos externo (CSD-E).)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 200
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 100
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state21
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 150
    F.4.2.2In the whole clinical trial 300
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Normal treatment for ALL
    Tratamiento habitual para LLA
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-09-17
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-09-07
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2017-01-04
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA